B-cell Lymphoma

Dear Colleagues,

B-cell lymphoma is a group of non-Hodgkin lymphoma transformed from normal B lymphocytes at various differentiation stages. B-cell lymphoma constitutes 85% of non-Hodgkin lymphoma which is the seventh most common type of cancer in the United States. Molecular biology of lymphomas, either tumor intrinsic or derived from the tumor microenvironment, is not only important for lymphoma diagnosis (such as MYC/BCL2/CCND1 gene rearrangements and MYD88 L265 mutation) and prognostic prediction, but also the key to uncover pathogenic mechanisms and identify therapeutic targets. For example, novel genetic models based on genetic drivers have been developed to classify diffuse large B-cell lymphoma (DLBCL), the most common type of B-cell lymphoma, which can be considered complementary to the GCB/ABC cell-of-origin classification based on normal B-cell gene-expression signatures maintained in lymphoma. Classification based on the lymphoma microenvironment characteristics is also being developed. Moreover, emerging single-cell sequencing technology has been applied in various types of B-cell lymphoma. Despite the sparsity, single-cell sequencing data have delineated molecular characteristics of distinct cell clusters and revealed deeper levels of biological heterogeneity for precision medicine. On the other hand, application of multiplexed imaging technology such as imaging mass cytometry reveals the spatial structure of the lymphoma immune microenvironment at the single-cell level. In B-cell lymphoma, we are also witnessing exciting advances in novel therapies changing clinical practice, including chimeric antigen receptor T-cell therapies and antibody-drug conjugates, as well as the promising bispecific T cell engager therapy. In this special edition, we welcome researches gaining new insights into lymphoma biology with implications for prognostic prediction, early detection, and therapy development.

Dr. Zijun Yidan Xu-Monette
Dr. Wenyu Shi
Dr. Yu Li
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.